Clinical Trial Update: Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 neoadjuvant immunoradiation trial for resectable non-small cell lung cancer. The study was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-10-16